Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin

Conclusions: In selected subgroups of patients with VTE, anti-Xa levels may represent a marker for the risk of developing recurrent VTE or bleeding events. Whether adjustment of the LMWH dosage would minimize this risk remains to be investigated in management studies.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Jara-Palomares, L., Marin-Romero, S., Asensio-Cruz, M. I., Elias-Hernandez, T., Ortega-Rivera, R., Otero-Candelera, R., Montero-Romero, E., Tallon-Aguilar, R., Ucero-Leon, M. D., Arellano-Ceballos, M., Ruiz-Serrano De La Espada, M. R., Fernandez-Garcia, C Tags: Pulmonary embolism Source Type: research